CAM
DFTX

Cresset Asset Management’s Definium Therapeutics DFTX Stock Holding History

Cresset Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-154,498
Closed -$565K – 1957
2023
Q4 		$565K Sell
154,498
-2,426
-2% -$7.3K ﹤0.01% 1169
2023
Q3 		$491K Sell
156,924
-2,575
-2% -$10.6K ﹤0.01% 1188
2023
Q2 		$569K Buy
+159,499
New +$550K ﹤0.01% 1215
2022
Q2 		– Sell
-6,740
Closed -$112K – 1037
2022
Q1 		$112K Sell
6,740
-6,667
-50% -$116K ﹤0.01% 937
2021
Q4 		$278K Buy
+13,407
New +$428K ﹤0.01% 914

Other funds holding DFTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Cresset Asset Management's DFTX Position: Q1 2024 in Review

Cresset Asset Management sold out of Definium Therapeutics (DFTX) in Q1 2024, closing a stake of 154,498 shares — an estimated $565K sold.

Cresset Asset Management first reported a position in DFTX in Q4 2021 and held it in 5 quarters. The position peaked at $569K in Q2 2023. 134 funds tracked by Wall St. Rank hold DFTX as of Q1 2024.

  • Cresset Asset Management reported no remaining Definium Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cresset Asset Management sold 154,498 Definium Therapeutics shares in Q1 2024, an estimated $565K.
  • Cresset Asset Management first reported a position in Definium Therapeutics in Q4 2021 and held it in 5 quarters.
  • Cresset Asset Management's Definium Therapeutics position peaked at $569K in Q2 2023.
  • 134 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2024.

Based on Cresset Asset Management's 13F filing for Q1 2024, filed 15 May 2024.